{"name":"Beijing Kawin Technology Share-Holding Co., Ltd.","slug":"beijing-kawin-technology-share-holding-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"PEG-IFN-SA /RBV","genericName":"PEG-IFN-SA /RBV","slug":"peg-ifn-sa-rbv","indication":"Chronic hepatitis C virus (HCV) infection","status":"phase_3"},{"name":"Pegasys /RBV","genericName":"Pegasys /RBV","slug":"pegasys-rbv","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1-6","status":"phase_3"}]}],"pipeline":[{"name":"PEG-IFN-SA /RBV","genericName":"PEG-IFN-SA /RBV","slug":"peg-ifn-sa-rbv","phase":"phase_3","mechanism":"PEG-IFN-SA is a pegylated interferon-alpha combined with ribavirin to stimulate antiviral immune responses and inhibit viral replication.","indications":["Chronic hepatitis C virus (HCV) infection"],"catalyst":""},{"name":"Pegasys /RBV","genericName":"Pegasys /RBV","slug":"pegasys-rbv","phase":"phase_3","mechanism":"Pegasys (peginterferon alfa-2a) is an interferon that activates the immune system to fight viral infections, while ribavirin (RBV) is a nucleoside analog that inhibits viral replication.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1-6"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9RaWNmdXFQNWpnQks1V2IzR0ZuY3FoTEJQLXpNSW1YV2t6dE9XVWxoclFPWlA3SUpFbTU3MlBiaTZ0VHRheXZaYjJORnpFLUk1T0JMdlpqMUtPdEJjTDRxemRIdw?oc=5","date":"2026-03-30","type":"pipeline","source":"GuruFocus","summary":"Stock List: Research Stocks from Around the World - GuruFocus","headline":"Stock List: Research Stocks from Around the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPWnZ6b3BxcWlYTnFiRHpxMmFFdDVWODF3QXV5NVprdzVEbkUtWk9oU0hOalZacUJhV2ZnWGpVZHYwVlQ0ZHQtX2lJWHUzdG1JSVowMXZPMDJHa2EzMWdCTjVMNTBydEtpQ1dWTWRlVjdWd0xNREh4UHRmeHZvTHd2NTJtUTc1TGluamZ6RzZpSTU?oc=5","date":"2017-11-12","type":"pipeline","source":"hkex.com.hk","summary":"Short Selling - hkex.com.hk","headline":"Short Selling","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}